A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess theSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in HealthyParticipants
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs ACH-0145228 (Primary) ; Ciprofloxacin
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Achillion Pharmaceuticals
- 26 Jul 2019 Status changed from recruiting to completed.
- 22 Jul 2019 According to an Achillion Pharmaceuticals Media Release, based on the results from this study the company plans to advance ACH-5228 into Phase 2 clinical trials in multiple diseases.
- 22 Jul 2019 According to an Achillion Pharmaceuticals Media Release, the company expects to submit an IND application to the U.S. Food and Drug Administration supporting clinical development for ACH-5228 in the fourth quarter of 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History